Newly identified personalized immunotherapy combination treats an aggressive form of advanced prostate cancer

Immunotherapies have been successful in treating many cancer conditions; however, not much success has yet been achieved in metastatic castrate-resistant prostate cancer (mCRPC). A study published March 2 in Clinical Cancer Research has revealed new insights into why immunotherapies don’t tend to work as well in prostate cancer.

Leave A Comment

Your email address will not be published. Required fields are marked *